WO2006138380A3 - Amine-containing lipids and uses thereof - Google Patents

Amine-containing lipids and uses thereof Download PDF

Info

Publication number
WO2006138380A3
WO2006138380A3 PCT/US2006/023171 US2006023171W WO2006138380A3 WO 2006138380 A3 WO2006138380 A3 WO 2006138380A3 US 2006023171 W US2006023171 W US 2006023171W WO 2006138380 A3 WO2006138380 A3 WO 2006138380A3
Authority
WO
WIPO (PCT)
Prior art keywords
lipids
amine
prepared
drug delivery
preparing
Prior art date
Application number
PCT/US2006/023171
Other languages
French (fr)
Other versions
WO2006138380A2 (en
Inventor
Daniel G Anderson
Andreas Zumbuehl
Elizaveta Sergeyevn Leshchiner
Robert S Langer
Michael Goldberg
Original Assignee
Massachusetts Inst Technology
Daniel G Anderson
Andreas Zumbuehl
Elizaveta Sergeyevn Leshchiner
Robert S Langer
Michael Goldberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology, Daniel G Anderson, Andreas Zumbuehl, Elizaveta Sergeyevn Leshchiner, Robert S Langer, Michael Goldberg filed Critical Massachusetts Inst Technology
Priority to EP06784878A priority Critical patent/EP1912679A4/en
Priority to CN200680029788.2A priority patent/CN101346468B/en
Priority to CA002611944A priority patent/CA2611944A1/en
Priority to JP2008517070A priority patent/JP5777846B2/en
Priority to AU2006259415A priority patent/AU2006259415B2/en
Publication of WO2006138380A2 publication Critical patent/WO2006138380A2/en
Publication of WO2006138380A3 publication Critical patent/WO2006138380A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/04—Formation of amino groups in compounds containing carboxyl groups
    • C07C227/10—Formation of amino groups in compounds containing carboxyl groups with simultaneously increasing the number of carbon atoms in the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/14—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of carbon skeletons containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/16—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/18—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Furan Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Nitrogen-containing lipids prepared from the conjugate addition of amines to acrylates, acrylamides, or other carbon-carbon double bonds conjugated to electron-withdrawing groups are described. Methods of preparing these lipids from commercially available starting materials are also provided. These amine-containing lipids or salts forms of these lipids are preferably biodegradable and biocompatible and may be used in a variety of drug delivery systems. Given the amino moiety of these lipids, they are particularly suited for the delivery of polynucleotides. Complexes or nanoparticles containing the inventive lipid and polynucleotide have been prepared. The inventive lipids may also be used to in preparing microparticle for drug delivery. They are particularly useful in delivering labile agents given their ability to buffer the pH of their surroundings.
PCT/US2006/023171 2005-06-15 2006-06-14 Amine-containing lipids and uses thereof WO2006138380A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP06784878A EP1912679A4 (en) 2005-06-15 2006-06-14 Amine-containing lipids and uses thereof
CN200680029788.2A CN101346468B (en) 2005-06-15 2006-06-14 Containing amine lipid and its purposes
CA002611944A CA2611944A1 (en) 2005-06-15 2006-06-14 Amine-containing lipids and uses thereof
JP2008517070A JP5777846B2 (en) 2005-06-15 2006-06-14 Amine-containing lipids and uses thereof
AU2006259415A AU2006259415B2 (en) 2005-06-15 2006-06-14 Amine-containing lipids and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US69060805P 2005-06-15 2005-06-15
US60/690,608 2005-06-15
US78517606P 2006-03-23 2006-03-23
US60/785,176 2006-03-23

Publications (2)

Publication Number Publication Date
WO2006138380A2 WO2006138380A2 (en) 2006-12-28
WO2006138380A3 true WO2006138380A3 (en) 2008-07-24

Family

ID=37571105

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/023171 WO2006138380A2 (en) 2005-06-15 2006-06-14 Amine-containing lipids and uses thereof

Country Status (7)

Country Link
US (2) US9006487B2 (en)
EP (2) EP2476756A1 (en)
JP (4) JP5777846B2 (en)
CN (1) CN101346468B (en)
AU (1) AU2006259415B2 (en)
CA (1) CA2611944A1 (en)
WO (1) WO2006138380A2 (en)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2611944A1 (en) * 2005-06-15 2006-12-28 Massachusetts Institute Of Technology Amine-containing lipids and uses thereof
CA2655933C (en) 2006-06-23 2014-09-09 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in cancer
DK2068886T3 (en) 2006-10-03 2013-11-18 Tekmira Pharmaceuticals Corp Lipid-containing preparations
AU2007337897A1 (en) * 2006-12-22 2008-07-03 Imuthes Limited Lipids and their use as non-viral delivery vehicle
TWI428135B (en) * 2007-03-26 2014-03-01 Hirofumi Takeuchi And a carrier composition for quick-acting nucleic acid delivery
US20110052673A1 (en) * 2008-01-29 2011-03-03 Arthur Tzianabos Therapeutic compositions
WO2009132131A1 (en) * 2008-04-22 2009-10-29 Alnylam Pharmaceuticals, Inc. Amino lipid based improved lipid formulation
AU2009303345B2 (en) * 2008-10-09 2015-08-20 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
WO2010048536A2 (en) * 2008-10-23 2010-04-29 Alnylam Pharmaceuticals, Inc. Processes for preparing lipids
WO2010062322A2 (en) * 2008-10-27 2010-06-03 Massachusetts Institute Of Technology Modulation of the immune response
CN102245773B (en) 2008-11-03 2014-08-27 阿莱斯亚生物疗法股份有限公司 Antibodies that specifically block the biological activity of a tumor antigen
JP6087504B2 (en) * 2008-11-07 2017-03-01 マサチューセッツ インスティテュート オブ テクノロジー Amino alcohol lipidoids and uses thereof
HUE037082T2 (en) * 2008-11-10 2018-08-28 Arbutus Biopharma Corp Novel lipids and compositions for the delivery of therapeutics
JP5317105B2 (en) * 2009-01-13 2013-10-16 国立大学法人 筑波大学 Complex of polymer fine particle derived from cross-linked polymer having quaternized amino group and nucleic acid
PL3338765T3 (en) 2009-12-01 2019-06-28 Translate Bio, Inc. Steroid derivative for the delivery of mrna in human genetic diseases
EP2567951B1 (en) * 2010-04-28 2018-09-19 Kyowa Hakko Kirin Co., Ltd. Cationic lipid
NZ605079A (en) * 2010-06-03 2015-08-28 Alnylam Pharmaceuticals Inc Biodegradable lipids for the delivery of active agents
EP2609135A4 (en) 2010-08-26 2015-05-20 Massachusetts Inst Technology Poly(beta-amino alcohols), their preparation, and uses thereof
EP2640700B1 (en) * 2010-11-15 2018-10-31 Life Technologies Corporation Amine-containing transfection reagents and methods for making and using same
RU2602171C2 (en) * 2011-03-24 2016-11-10 Лео Фарма А/С Composition containing lipid nanoparticles and corticosteroid or vitamin d derivative
PL2691443T3 (en) 2011-03-28 2021-08-30 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
RS59080B1 (en) 2011-03-31 2019-09-30 Adc Therapeutics Sa Antibodies against kidney associated antigen 1 and antigen binding fragments thereof
DK2718261T3 (en) * 2011-06-08 2016-03-29 Nitto Denko Corp Compounds to target drug delivery and promote siRNA activity
EP4043025A1 (en) 2011-06-08 2022-08-17 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mrna delivery
US9126966B2 (en) 2011-08-31 2015-09-08 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use thereof
CN103958460B (en) * 2011-10-05 2016-04-06 阿克马法国公司 Aminocompound, the polymkeric substance comprising it and uses thereof that poly-hydroxy replaces
AU2012328570B2 (en) 2011-10-27 2017-08-31 Massachusetts Institute Of Technology Amino acid derivatives functionalized on the n-terminus capable of forming drug encapsulating microspheres and uses thereof
ES2921724T1 (en) 2011-12-07 2022-08-31 Alnylam Pharmaceuticals Inc Biodegradable lipids for the administration of active agents
WO2013086373A1 (en) * 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
CA2859205A1 (en) 2011-12-16 2013-06-20 Massachusetts Institute Of Technology Alpha-aminoamidine polymers and uses thereof
US20170174753A1 (en) 2012-01-09 2017-06-22 Alethia Biotherapeutics Inc. Method for treating breast cancer
EP2859102A4 (en) 2012-06-08 2016-05-11 Shire Human Genetic Therapies Nuclease resistant polynucleotides and uses thereof
TW201726600A (en) 2012-07-06 2017-08-01 協和醱酵麒麟有限公司 Cationic lipid
WO2014028487A1 (en) 2012-08-13 2014-02-20 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
WO2014089486A1 (en) 2012-12-07 2014-06-12 Shire Human Genetic Therapies, Inc. Lipidic nanoparticles for mrna delivering
WO2014152940A1 (en) 2013-03-14 2014-09-25 Shire Human Genetic Therapies, Inc. Mrna therapeutic compositions and use to treat diseases and disorders
PT2968586T (en) 2013-03-14 2018-11-13 Ethris Gmbh Cftr mrna compositions and related methods and uses
EP2970955B1 (en) 2013-03-14 2018-11-14 Translate Bio, Inc. Methods for purification of messenger rna
CA2903882A1 (en) 2013-03-15 2014-09-18 Mirna Therapeutics, Inc. Combination cancer treatments utilizing micrornas and egfr-tki inhibitors
US9315472B2 (en) 2013-05-01 2016-04-19 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
WO2014186366A1 (en) 2013-05-13 2014-11-20 Tufts University Nanocomplexes for delivery of saporin
EP3013975A1 (en) 2013-06-24 2016-05-04 Mirna Therapeutics, Inc. Biomarkers of mir-34 activity
EA036400B1 (en) 2013-06-28 2020-11-06 Этрис Гмбх Compositions for introducing rna into cells
JP2016538829A (en) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Polynucleotide encoding low density lipoprotein receptor
WO2015061491A1 (en) 2013-10-22 2015-04-30 Shire Human Genetic Therapies, Inc. Mrna therapy for phenylketonuria
US9629804B2 (en) 2013-10-22 2017-04-25 Shire Human Genetic Therapies, Inc. Lipid formulations for delivery of messenger RNA
AU2014340092B2 (en) 2013-10-22 2019-09-19 Translate Bio, Inc. mRNA therapy for Argininosuccinate Synthetase Deficiency
RU2016138020A (en) 2014-02-26 2018-03-29 Этрис Гмбх COMPOSITIONS FOR ADMINISTRATION OF PHK IN THE GASTROINTESTINAL TRACT
EP3126496A1 (en) 2014-04-01 2017-02-08 Mirna Therapeutics, Inc. Microrna dosing regimens
SG11201608725YA (en) 2014-04-25 2016-11-29 Shire Human Genetic Therapies Methods for purification of messenger rna
MA48050A (en) 2014-05-30 2020-02-12 Translate Bio Inc BIODEGRADABLE LIPIDS FOR THE ADMINISTRATION OF NUCLEIC ACIDS
CA2951707A1 (en) 2014-06-10 2015-12-17 Massachusetts Institute Of Technology Method for gene editing
WO2015200465A1 (en) 2014-06-24 2015-12-30 Shire Human Genetic Therapies, Inc. Stereochemically enriched compositions for delivery of nucleic acids
SI3766916T1 (en) 2014-06-25 2023-01-31 Acuitas Therapeutics Inc. Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2016004202A1 (en) 2014-07-02 2016-01-07 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
US10736966B2 (en) 2014-08-12 2020-08-11 Massachusetts Institute Of Technology Brush-poly (glycoamidoamine)-lipids and uses thereof
US9339029B2 (en) 2014-09-04 2016-05-17 Preceres Inc. Hydrazinyl lipidoids and uses thereof
EP3034539A1 (en) 2014-12-19 2016-06-22 Ethris GmbH Compositions for introducing nucleic acid into cells
CA2984125A1 (en) * 2015-04-27 2016-11-03 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
US10201618B2 (en) 2015-06-19 2019-02-12 Massachusetts Institute Of Technology Alkenyl substituted 2,5-piperazinediones, compositions, and uses thereof
WO2017004143A1 (en) 2015-06-29 2017-01-05 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2017007552A1 (en) 2015-07-06 2017-01-12 The University Of Florida Research Foundation, Inc. Ph-sensitive nanoparticles for detecting and preventing food spoilage
KR20240027890A (en) 2015-09-14 2024-03-04 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Lipocationic dendrimers and uses thereof
AU2016324310B2 (en) 2015-09-17 2021-04-08 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
EP3362102A1 (en) 2015-10-14 2018-08-22 Life Technologies Corporation Ribonucleoprotein transfection agents
CN113636947A (en) * 2015-10-28 2021-11-12 爱康泰生治疗公司 Novel lipid and lipid nanoparticle formulations for delivery of nucleic acids
PL3394030T3 (en) 2015-12-22 2022-04-11 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
WO2017158093A1 (en) * 2016-03-17 2017-09-21 Københavns Universitet Nanoparticle compositions comprising plga derivatives and a lipid
DK3463483T3 (en) 2016-05-27 2024-03-04 Transcriptx Inc Treatment of primary ciliary dyskinesia with synthetic messenger RNA
AU2017286606A1 (en) 2016-06-14 2018-12-13 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
BR112019008481A2 (en) * 2016-10-26 2020-03-03 Curevac Ag LIPID NANOPARTICLE MRNA VACCINES
WO2018089540A1 (en) 2016-11-08 2018-05-17 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
US11241490B2 (en) 2017-01-11 2022-02-08 The Trustees Of The University Of Pennsylvania Nucleoside-modified RNA for inducing an immune response against zika virus
WO2018157154A2 (en) 2017-02-27 2018-08-30 Translate Bio, Inc. Novel codon-optimized cftr mrna
EP3596042B1 (en) 2017-03-15 2022-01-12 Modernatx, Inc. Crystal forms of amino lipids
HUE060693T2 (en) 2017-03-15 2023-04-28 Modernatx Inc Compound and compositions for intracellular delivery of therapeutic agents
US11357856B2 (en) 2017-04-13 2022-06-14 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
CN110799492B (en) 2017-04-28 2023-06-27 爱康泰生治疗公司 Novel carbonyl lipid and lipid nanoparticle formulations for delivery of nucleic acids
EP3624824A1 (en) 2017-05-16 2020-03-25 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
EP3668833A1 (en) 2017-08-16 2020-06-24 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
WO2019036030A1 (en) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
WO2019036028A1 (en) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
US11464860B2 (en) 2017-10-27 2022-10-11 Massachusetts Institute Of Technology Poly (beta-amino esters) and uses thereof
CN112399860A (en) 2018-06-06 2021-02-23 麻省理工学院 Circular RNA for translation in eukaryotic cells
AU2019325702A1 (en) 2018-08-24 2021-02-25 Translate Bio, Inc. Methods for purification of messenger RNA
JP7450945B2 (en) 2018-08-30 2024-03-18 テナヤ セラピューティクス， インコーポレイテッド Cardiac cell reprogramming using myocardin and ASCL1
GB2600800B (en) 2018-09-04 2023-08-16 Univ Texas Compositions and methods for organ specific delivery of nucleic acids
CN112996519A (en) 2018-09-04 2021-06-18 德克萨斯大学系统董事会 Compositions and methods for organ-specific delivery of nucleic acids
US20210403950A1 (en) * 2018-11-13 2021-12-30 Oncorus, Inc. Encapsulated polynucleotides and methods of use
EP3908568A1 (en) 2019-01-11 2021-11-17 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
CA3139032A1 (en) 2019-05-22 2020-11-26 Robert Alexander WESSELHOEFT Circular rna compositions and methods
US20230137971A1 (en) 2019-07-11 2023-05-04 Tenaya Therapeutics Inc. Cardiac cell reprogramming with micrornas and other factors
JP2022548304A (en) 2019-09-19 2022-11-17 モデルナティエックス インコーポレイテッド Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
EP3920976B1 (en) 2019-12-04 2023-07-19 Orna Therapeutics, Inc. Circular rna compositions and methods
KR102198736B1 (en) 2020-01-15 2021-01-05 이화여자대학교 산학협력단 Lipid nanoparticles for in vivo drug delivery and uses thereof
US20230097743A1 (en) * 2020-03-02 2023-03-30 Trustees Of Tufts College Imidazole-based synthetic lipidoids for in vivo mrna delivery into immune cells
AU2021230476A1 (en) 2020-03-02 2022-10-20 Tenaya Therapeutics, Inc. Gene vector control by cardiomyocyte-expressed microRNAs
CN113521268A (en) 2020-04-22 2021-10-22 生物技术Rna制药有限公司 Coronavirus vaccine
CN115010990A (en) * 2020-11-11 2022-09-06 绍兴瑞康生物科技有限公司 Steric-hindrance-adjustable weak-base light stabilizer and preparation method and application thereof
EP4255432A1 (en) * 2020-12-07 2023-10-11 Trustees Of Tufts College Lipidoid compositions and methods of use thereof
WO2022152109A2 (en) * 2021-01-14 2022-07-21 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
CN116887812A (en) 2021-02-26 2023-10-13 埃泽瑞斯公司 Formulations for aerosol formation and aerosols for delivery of nucleic acids
EP4305088A1 (en) 2021-03-09 2024-01-17 Massachusetts Institute of Technology Branched poly(-amino esters) for the delivery of nucleic acids
US20230263742A1 (en) * 2021-05-06 2023-08-24 Stemirna Therapeutics Co., Ltd. A lipid
EP4342881A1 (en) * 2021-05-20 2024-03-27 Beijing Institute Of Technology Compound, liposome, and uses thereof
KR20240013087A (en) 2021-05-24 2024-01-30 쑤저우 아보젠 바이오사이언시스 컴퍼니 리미티드 Lipid Compounds and Lipid Nanoparticle Compositions
CN113461577B (en) * 2021-09-01 2021-12-14 中山大学附属第七医院(深圳) Amino lipid and application thereof
WO2023059806A1 (en) 2021-10-06 2023-04-13 Massachusetts Institute Of Technology Lipid nanoparticles for drug delivery to microglia in the brain
WO2023107400A1 (en) * 2021-12-06 2023-06-15 Ohio State Innovation Foundation Diamino lipid (dal) compounds and pharmaceutical compositions comprising an immunotherapeutic agent
CN116514672A (en) * 2022-01-30 2023-08-01 康希诺生物股份公司 Novel ionizable lipids for nucleic acid delivery and LNP compositions and vaccines thereof
CN116554042A (en) * 2022-01-30 2023-08-08 康希诺生物股份公司 Novel ionizable lipids for nucleic acid delivery and LNP compositions and vaccines thereof
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
CN115557851B (en) * 2022-06-27 2023-04-18 上海云沂生物医药科技有限公司 Amino lipid, synthetic method, particle and application thereof
EP4327829A1 (en) 2022-08-26 2024-02-28 Ethris GmbH Stabilization of lipid or lipidoid nanoparticle suspensions
WO2024042236A1 (en) 2022-08-26 2024-02-29 Ethris Gmbh Stable lipid or lipidoid nanoparticle suspensions
CN115677518B (en) * 2023-01-05 2023-04-14 北京悦康科创医药科技股份有限公司 Ionizable cationic lipid compounds and compositions for delivery of nucleic acids and uses
CN116535381B (en) * 2023-07-06 2023-10-17 北京悦康科创医药科技股份有限公司 Cationic lipid compound having five-membered ring acetal structure, composition containing same and use
CN116854606B (en) * 2023-09-05 2023-12-22 苏州科睿思制药有限公司 Cationic lipid compound, composition and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4762915A (en) * 1985-01-18 1988-08-09 Liposome Technology, Inc. Protein-liposome conjugates

Family Cites Families (186)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US533088A (en) * 1895-01-29 Car-coupling
US2580922A (en) * 1942-09-19 1952-01-01 Nat Aluminate Corp Prevention of foaming in steam generation
US2647121A (en) * 1951-02-02 1953-07-28 Ruth P Jacoby Diamine-bis-acetamides
US2819718A (en) * 1953-07-16 1958-01-14 Isidore H Goldman Drainage tube
US2717909A (en) 1953-09-24 1955-09-13 Monsanto Chemicals Hydroxyethyl-keryl-alkylene-ammonium compounds
US2844629A (en) * 1956-04-25 1958-07-22 American Home Prod Fatty acid amides and derivatives thereof
US3096560A (en) * 1958-11-21 1963-07-09 William J Liebig Process for synthetic vascular implants
US3170953A (en) * 1960-09-06 1965-02-23 Dow Chemical Co N-hydroxymaleamic acid
DE1155118B (en) * 1961-12-30 1963-10-03 Basf Ag Process for the preparation of sulfonamides substituted on the nitrogen atom
GB1072118A (en) 1962-12-01 1967-06-14 Sandoz Ag Amides of aminopropionic acid
FR1378382A (en) * 1962-12-01 1964-11-13 Sandoz Sa Amides of amino-propionic acid, usable in particular for the treatment of textile fibers
JPS5141663B1 (en) * 1966-03-12 1976-11-11
JPS4822365B1 (en) 1968-10-25 1973-07-05
NL143127B (en) * 1969-02-04 1974-09-16 Rhone Poulenc Sa REINFORCEMENT DEVICE FOR A DEFECTIVE HEART VALVE.
US3614954A (en) * 1970-02-09 1971-10-26 Medtronic Inc Electronic standby defibrillator
US3614955A (en) * 1970-02-09 1971-10-26 Medtronic Inc Standby defibrillator and method of operation
US3945052A (en) * 1972-05-01 1976-03-23 Meadox Medicals, Inc. Synthetic vascular graft and method for manufacturing the same
US3805301A (en) * 1972-07-28 1974-04-23 Meadox Medicals Inc Tubular grafts having indicia thereon
JPS49127908A (en) 1973-04-20 1974-12-07
JPS5624664B2 (en) 1973-06-28 1981-06-08
US4013507A (en) * 1973-09-18 1977-03-22 California Institute Of Technology Ionene polymers for selectively inhibiting the vitro growth of malignant cells
JPS5123537A (en) 1974-04-26 1976-02-25 Adeka Argus Chemical Co Ltd KASOZAISOSEIBUTSU
GB1527592A (en) * 1974-08-05 1978-10-04 Ici Ltd Wound dressing
US3995623A (en) 1974-12-23 1976-12-07 American Hospital Supply Corporation Multipurpose flow-directed catheter
JPS5524302Y2 (en) 1975-03-31 1980-06-10
US4281669A (en) * 1975-05-09 1981-08-04 Macgregor David C Pacemaker electrode with porous system
JPS5210847A (en) 1975-07-16 1977-01-27 Nippon Steel Corp Pinch roll
US4096860A (en) * 1975-10-08 1978-06-27 Mclaughlin William F Dual flow encatheter
CA1069652A (en) * 1976-01-09 1980-01-15 Alain F. Carpentier Supported bioprosthetic heart valve with compliant orifice ring
US4134402A (en) * 1976-02-11 1979-01-16 Mahurkar Sakharam D Double lumen hemodialysis catheter
US4072146A (en) * 1976-09-08 1978-02-07 Howes Randolph M Venous catheter device
US4335723A (en) * 1976-11-26 1982-06-22 The Kendall Company Catheter having inflatable retention means
US4099528A (en) * 1977-02-17 1978-07-11 Sorenson Research Co., Inc. Double lumen cannula
US4140126A (en) * 1977-02-18 1979-02-20 Choudhury M Hasan Method for performing aneurysm repair
US4182833A (en) * 1977-12-07 1980-01-08 Celanese Polymer Specialties Company Cationic epoxide-amine reaction products
US4180068A (en) 1978-04-13 1979-12-25 Motion Control, Incorporated Bi-directional flow catheter with retractable trocar/valve structure
DE2960875D1 (en) * 1978-04-19 1981-12-10 Ici Plc A method of preparing a tubular product by electrostatic spinning
US4284459A (en) * 1978-07-03 1981-08-18 The Kendall Company Method for making a molded catheter
US4227533A (en) * 1978-11-03 1980-10-14 Bristol-Myers Company Flushable urinary catheter
US4375817A (en) * 1979-07-19 1983-03-08 Medtronic, Inc. Implantable cardioverter
DE3010841A1 (en) * 1980-03-21 1981-10-08 Ulrich Dr.med. 6936 Haag Uthmann CATHEDER
US4339369A (en) * 1981-04-23 1982-07-13 Celanese Corporation Cationic epoxide-amine reaction products
US4406656A (en) * 1981-06-01 1983-09-27 Brack Gillium Hattler Venous catheter having collapsible multi-lumens
US4475972A (en) * 1981-10-01 1984-10-09 Ontario Research Foundation Implantable material
US4401472A (en) 1982-02-26 1983-08-30 Martin Marietta Corporation Hydraulic cement mixes and processes for improving hydraulic cement mixes
US4568329A (en) * 1982-03-08 1986-02-04 Mahurkar Sakharam D Double lumen catheter
US4546499A (en) * 1982-12-13 1985-10-15 Possis Medical, Inc. Method of supplying blood to blood receiving vessels
US4530113A (en) * 1983-05-20 1985-07-23 Intervascular, Inc. Vascular grafts with cross-weave patterns
US4647416A (en) * 1983-08-03 1987-03-03 Shiley Incorporated Method of preparing a vascular graft prosthesis
US4550447A (en) * 1983-08-03 1985-11-05 Shiley Incorporated Vascular graft prosthesis
US5104399A (en) * 1986-12-10 1992-04-14 Endovascular Technologies, Inc. Artificial graft and implantation method
US4571241A (en) * 1983-12-16 1986-02-18 Christopher T Graham Urinary catheter with collapsible urethral tube
US4710169A (en) 1983-12-16 1987-12-01 Christopher T Graham Urinary catheter with collapsible urethral tube
US5197977A (en) * 1984-01-30 1993-03-30 Meadox Medicals, Inc. Drug delivery collagen-impregnated synthetic vascular graft
US4737518A (en) 1984-04-03 1988-04-12 Takeda Chemical Industries, Ltd. Lipid derivatives, their production and use
US4562596A (en) * 1984-04-25 1986-01-07 Elliot Kornberg Aortic graft, device and method for performing an intraluminal abdominal aortic aneurysm repair
US4782836A (en) * 1984-05-24 1988-11-08 Intermedics, Inc. Rate adaptive cardiac pacemaker responsive to patient activity and temperature
US4662382A (en) * 1985-01-16 1987-05-05 Intermedics, Inc. Pacemaker lead with enhanced sensitivity
US4860751A (en) * 1985-02-04 1989-08-29 Cordis Corporation Activity sensor for pacemaker control
CA1320724C (en) * 1985-07-19 1993-07-27 Koichi Kanehira Terpene amino alcohols and medicinal uses thereof
US4701162A (en) * 1985-09-24 1987-10-20 The Kendall Company Foley catheter assembly
EP0255899B1 (en) * 1986-07-31 1992-07-15 Werner Prof. Dr.-Ing. Irnich Rate adaptive pacemaker
US4960409A (en) * 1986-09-11 1990-10-02 Catalano Marc L Method of using bilumen peripheral venous catheter with adapter
JPH0829776B2 (en) * 1986-10-29 1996-03-27 東燃化学株式会社 Synthetic resin container and mold for manufacturing the same
US4720517A (en) * 1986-11-24 1988-01-19 Ciba-Geigy Corporation Compositions stabilized with N-hydroxyiminodiacetic and dipropionic acids and esters thereof
US5138067A (en) 1987-12-17 1992-08-11 Shionogi & Co. Ltd. Lipid derivatives
US5047540A (en) 1987-12-17 1991-09-10 Shionogi & Co., Ltd. Lipid derivatives
US4892540A (en) * 1988-04-21 1990-01-09 Sorin Biomedica S.P.A. Two-leaflet prosthetic heart valve
US5176661A (en) * 1988-09-06 1993-01-05 Advanced Cardiovascular Systems, Inc. Composite vascular catheter
US5024671A (en) * 1988-09-19 1991-06-18 Baxter International Inc. Microporous vascular graft
US5200395A (en) 1988-10-18 1993-04-06 Ajinomoto Company, Inc. Pharmaceutical composition of BUF-5 for treating anemia
CA2001401A1 (en) 1988-10-25 1990-04-25 Claude Piantadosi Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions
US5101824A (en) * 1990-04-16 1992-04-07 Siemens-Pacesetter, Inc. Rate-responsive pacemaker with circuitry for processing multiple sensor inputs
US5405379A (en) * 1990-07-26 1995-04-11 Lane; Rodney J. Self expanding vascular endoprosthesis for aneurysms
US5693338A (en) 1994-09-29 1997-12-02 Emisphere Technologies, Inc. Diketopiperazine-based delivery systems
JPH0765267B2 (en) * 1990-08-22 1995-07-12 花王株式会社 Softening agent
DE9117152U1 (en) * 1990-10-09 1996-07-11 Cook Inc Stent
ATE120971T1 (en) 1990-12-19 1995-04-15 Osypka Peter PACEMAKER LEAD WITH AN INNER CHANNEL AND WITH AN ELECTRODE HEAD.
US5116360A (en) * 1990-12-27 1992-05-26 Corvita Corporation Mesh composite graft
US5405363A (en) * 1991-03-15 1995-04-11 Angelon Corporation Implantable cardioverter defibrillator having a smaller displacement volume
US5330768A (en) * 1991-07-05 1994-07-19 Massachusetts Institute Of Technology Controlled drug delivery using polymer/pluronic blends
US5545449A (en) 1991-10-02 1996-08-13 Weyerhaeuser Company Polyether-reinforced fiber-based materials
US5151105A (en) * 1991-10-07 1992-09-29 Kwan Gett Clifford Collapsible vessel sleeve implant
JP2684276B2 (en) * 1991-11-27 1997-12-03 富士写真フイルム株式会社 Silver halide color photographic materials
US5284491A (en) * 1992-02-27 1994-02-08 Medtronic, Inc. Cardiac pacemaker with hysteresis behavior
US5352461A (en) * 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
SE9200951D0 (en) 1992-03-27 1992-03-27 Kabi Pharmacia Ab PHARMACEUTICAL COMPOSITION CONTAINING A DEFINED LIPID SYSTEM
KR950702628A (en) * 1992-08-01 1995-07-29 치세이 라 Antiallergic Agents
US5461223A (en) * 1992-10-09 1995-10-24 Eastman Kodak Company Bar code detecting circuitry
US5300022A (en) * 1992-11-12 1994-04-05 Martin Klapper Urinary catheter and bladder irrigation system
US5496362A (en) 1992-11-24 1996-03-05 Cardiac Pacemakers, Inc. Implantable conformal coil patch electrode with multiple conductive elements for cardioversion and defibrillation
US5716395A (en) * 1992-12-11 1998-02-10 W.L. Gore & Associates, Inc. Prosthetic vascular graft
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5697953A (en) 1993-03-13 1997-12-16 Angeion Corporation Implantable cardioverter defibrillator having a smaller displacement volume
US5314430A (en) * 1993-06-24 1994-05-24 Medtronic, Inc. Atrial defibrillator employing transvenous and subcutaneous electrodes and method of use
DE4325848A1 (en) 1993-07-31 1995-02-02 Basf Ag Process for the preparation of N- (2-hydroxyethyl) piperazine
EP0875280B1 (en) * 1993-10-06 2001-08-22 The Kansai Electric Power Co., Inc. Method for removing carbon dioxide from combustion exhaust gas
US5609624A (en) * 1993-10-08 1997-03-11 Impra, Inc. Reinforced vascular graft and method of making same
SE9303481L (en) 1993-10-22 1995-04-23 Berol Nobel Ab hygiene composition
AU1091095A (en) 1993-11-08 1995-05-29 Harrison M. Lazarus Intraluminal vascular graft and method
JPH09505593A (en) 1993-11-24 1997-06-03 メガバイオス・コーポレイション Amphiphilic derivatives of piperazine
FR2714830B1 (en) * 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition containing nucleic acids, preparation and uses.
FR2716110B1 (en) * 1994-02-16 1996-04-05 Roussel Uclaf Cosmetic or pharmaceutical compositions comprising liposomes.
US5776747A (en) * 1994-07-20 1998-07-07 Cytotherapeutics, Inc. Method for controlling the distribution of cells within a bioartificial organ using polycthylene oxide-poly (dimethylsiloxane) copolymer
FR2730637B1 (en) * 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa PHARMACEUTICAL COMPOSITION CONTAINING NUCLEIC ACIDS, AND USES THEREOF
US5830430A (en) * 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
EP0822835A1 (en) 1995-04-17 1998-02-11 Imarx Pharmaceutical Corp. Hybrid magnetic resonance contrast agents
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
US5772694A (en) * 1995-05-16 1998-06-30 Medical Carbon Research Institute L.L.C. Prosthetic heart valve with improved blood flow
US5609629A (en) * 1995-06-07 1997-03-11 Med Institute, Inc. Coated implantable medical device
US5607385A (en) * 1995-08-17 1997-03-04 Medtronic, Inc. Device and algorithm for a combined cardiomyostimulator and a cardiac pacer-carioverter-defibrillator
FR2740978B1 (en) * 1995-11-10 1998-01-02 Ela Medical Sa IMPLANTABLE DEFIBRILLATOR / CARDIOVERVER ACTIVE MEDICAL DEVICE
FR2741066B1 (en) * 1995-11-14 1997-12-12 Rhone Poulenc Rorer Sa NEW TRANSFECTION AGENTS AND THEIR PHARMACEUTICAL APPLICATIONS
US5874105A (en) 1996-01-31 1999-02-23 Collaborative Laboratories, Inc. Lipid vesicles formed with alkylammonium fatty acid salts
US5913848A (en) * 1996-06-06 1999-06-22 Luther Medical Products, Inc. Hard tip over-the-needle catheter and method of manufacturing the same
US5736573A (en) 1996-07-31 1998-04-07 Galat; Alexander Lipid and water soluble derivatives of drugs
US6887665B2 (en) * 1996-11-14 2005-05-03 Affymetrix, Inc. Methods of array synthesis
US6204297B1 (en) * 1996-11-26 2001-03-20 Rhodia Inc. Nonionic gemini surfactants
FR2760193B1 (en) 1997-02-28 1999-05-28 Transgene Sa LIPIDS AND COMPLEXES OF CATIONIC LIPIDS AND ACTIVE SUBSTANCES, IN PARTICULAR FOR THE TRANSFECTION OF CELLS
US5837283A (en) 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
US5945326A (en) 1997-03-20 1999-08-31 New England Biolabs, Inc. Method for cloning and producing the Spel restriction endonuclease
US5958894A (en) * 1997-04-04 1999-09-28 Megabios Corporation Amphiphilic biguanide derivatives
JPH115786A (en) 1997-06-13 1999-01-12 Pola Chem Ind Inc Novel aminohydroxypropylpiperazine derivative
US6067471A (en) * 1998-08-07 2000-05-23 Cardiac Pacemakers, Inc. Atrial and ventricular implantable cardioverter-defibrillator and lead system
JPH1180142A (en) 1997-09-05 1999-03-26 Pola Chem Ind Inc Production of diphenylalkyl compound
US6096075A (en) * 1998-01-22 2000-08-01 Medical Carbon Research Institute, Llc Prosthetic heart valve
US6013429A (en) * 1998-02-27 2000-01-11 Eastman Kodak Company Photographic element with new singlet oxygen quenchers
US6271209B1 (en) 1998-04-03 2001-08-07 Valentis, Inc. Cationic lipid formulation delivering nucleic acid to peritoneal tumors
US6176877B1 (en) * 1998-04-20 2001-01-23 St. Jude Medical, Inc. Two piece prosthetic heart valve
NO313244B1 (en) 1998-07-08 2002-09-02 Crew Dev Corp Process for the isolation and production of magnesite or magnesium chloride
US6055454A (en) * 1998-07-27 2000-04-25 Cardiac Pacemakers, Inc. Cardiac pacemaker with automatic response optimization of a physiologic sensor based on a second sensor
US6299604B1 (en) * 1998-08-20 2001-10-09 Cook Incorporated Coated implantable medical device
WO2000030444A1 (en) * 1998-11-25 2000-06-02 Vanderbilt University Cationic liposomes for gene transfer
US6169923B1 (en) * 1999-04-23 2001-01-02 Pacesetter, Inc. Implantable cardioverter-defibrillator with automatic arrhythmia detection criteria adjustment
US6696424B1 (en) * 1999-05-28 2004-02-24 Vical Incorporated Cytofectin dimers and methods of use thereof
DE60036950T2 (en) 1999-08-27 2008-08-07 Inex Pharmaceuticals Corp., Burnaby COMPOSITIONS FOR STIMULATING CYTOKIN SECRETION AND INDUCING AN IMMUNE RESPONSE
US6358278B1 (en) * 1999-09-24 2002-03-19 St. Jude Medical, Inc. Heart valve prosthesis with rotatable cuff
US6371983B1 (en) * 1999-10-04 2002-04-16 Ernest Lane Bioprosthetic heart valve
CN1433478A (en) 1999-12-30 2003-07-30 诺瓦提斯公司 Novel colloid synthetic vectors for gene therapy
US6370434B1 (en) * 2000-02-28 2002-04-09 Cardiac Pacemakers, Inc. Cardiac lead and method for lead implantation
US6565960B2 (en) 2000-06-01 2003-05-20 Shriners Hospital Of Children Polymer composite compositions
US6998115B2 (en) * 2000-10-10 2006-02-14 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US20020094528A1 (en) * 2000-11-29 2002-07-18 Salafsky Joshua S. Method and apparatus using a surface-selective nonlinear optical technique for detection of probe-target interations
JP2002167368A (en) * 2000-12-01 2002-06-11 Nitto Denko Corp Alkyl group-substituted dendrimer and method for preparing the same
US20020192721A1 (en) 2001-03-28 2002-12-19 Engeneos, Inc. Modular molecular clasps and uses thereof
KR100823815B1 (en) 2001-04-23 2008-04-21 신에쓰 가가꾸 고교 가부시끼가이샤 Novel Tertiary Amine Compounds Having an Ester Structure and Processes for Preparing Same
FR2825370A1 (en) 2001-05-31 2002-12-06 Inst Nat Sante Rech Med KERATINOCYTES OBTAINED FROM MAMMALIAN EMBRYONIC STEM CELLS
EP2428571B1 (en) * 2001-09-28 2018-07-18 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. MicroRNA molecules
CA2466328A1 (en) 2001-11-09 2003-05-15 Bayer Healthcare Ag Isotopically coded affinity markers 3
DE10207178A1 (en) * 2002-02-19 2003-09-04 Novosom Ag Components for the production of amphoteric liposomes
US20030215395A1 (en) 2002-05-14 2003-11-20 Lei Yu Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier
US7601367B2 (en) 2002-05-28 2009-10-13 Mirus Bio Llc Compositions and processes using siRNA, amphipathic compounds and polycations
US20040028804A1 (en) 2002-08-07 2004-02-12 Anderson Daniel G. Production of polymeric microarrays
EP1539936A2 (en) 2002-08-22 2005-06-15 Celltran Limited Cell culture surface
JP2006515574A (en) 2002-11-22 2006-06-01 ノボ・ノルデイスク・エー／エス Compounds used in the treatment of obesity
US7619017B2 (en) 2003-05-19 2009-11-17 Wacker Chemical Corporation Polymer emulsions resistant to biodeterioration
WO2005007810A2 (en) * 2003-06-16 2005-01-27 Grinstaff Mark W Functional synthetic molecules and macromolecules for gene delivery
WO2005028619A2 (en) 2003-09-15 2005-03-31 Massachusetts Institute Of Technology Nanoliter-scale synthesis of arrayed biomaterials and screening thereof
US20050123596A1 (en) * 2003-09-23 2005-06-09 Kohane Daniel S. pH-triggered microparticles
US20050069590A1 (en) 2003-09-30 2005-03-31 Buehler Gail K. Stable suspensions for medicinal dosages
EP1683784A4 (en) 2003-11-10 2007-08-22 Nippon Kayaku Kk Diimonium salt compound and use thereof
US7022214B2 (en) 2004-01-21 2006-04-04 Bio-Rad Laboratories, Inc. Carrier ampholytes of high pH range
US7556684B2 (en) 2004-02-26 2009-07-07 Construction Research & Technology Gmbh Amine containing strength improvement admixture
US20060228404A1 (en) * 2004-03-04 2006-10-12 Anderson Daniel G Compositions and methods for treatment of hypertrophic tissues
DE102004043342A1 (en) 2004-09-08 2006-03-09 Bayer Materialscience Ag Blocked polyurethane prepolymers as adhesives
GB0502482D0 (en) * 2005-02-07 2005-03-16 Glaxo Group Ltd Novel compounds
CA2611944A1 (en) 2005-06-15 2006-12-28 Massachusetts Institute Of Technology Amine-containing lipids and uses thereof
US20090221684A1 (en) * 2005-12-22 2009-09-03 Trustees Of Boston University Molecules for Gene Delivery and Gene Therapy, and Methods of Use Thereof
US20070275923A1 (en) 2006-05-25 2007-11-29 Nastech Pharmaceutical Company Inc. CATIONIC PEPTIDES FOR siRNA INTRACELLULAR DELIVERY
US8808681B2 (en) * 2006-06-05 2014-08-19 Massachusetts Institute Of Technology Crosslinked, degradable polymers and uses thereof
ES2293834B1 (en) 2006-07-20 2009-02-16 Consejo Superior Investig. Cientificas COMPOSED WITH INHIBITING ACTIVITY OF UBC13-UEV INTERACTIONS, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE IT AND ITS THERAPEUTIC APPLICATIONS.
EP2046266A4 (en) * 2006-07-21 2009-11-04 Massachusetts Inst Technology End-modified poly(beta-amino esters) and uses thereof
DK2068886T3 (en) * 2006-10-03 2013-11-18 Tekmira Pharmaceuticals Corp Lipid-containing preparations
WO2008113364A2 (en) 2007-03-20 2008-09-25 Recepticon Aps Amino derivatives to prevent nephrotoxicity and cancer
WO2008137470A1 (en) * 2007-05-01 2008-11-13 Pgr-Solutions Multi-chain lipophilic polyamines
EP2197495A2 (en) 2007-10-02 2010-06-23 MDRNA, Inc. Lipopeptides for delivery of nucleic acids
CN104382853A (en) 2008-10-16 2015-03-04 玛瑞纳生物技术有限公司 Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics
WO2010062322A2 (en) * 2008-10-27 2010-06-03 Massachusetts Institute Of Technology Modulation of the immune response
JP6087504B2 (en) 2008-11-07 2017-03-01 マサチューセッツ インスティテュート オブ テクノロジー Amino alcohol lipidoids and uses thereof
EP2415124B1 (en) 2009-04-02 2017-02-15 The Siemon Company Telecommunications patch panel
JP5769701B2 (en) 2009-05-05 2015-08-26 テクミラ ファーマシューティカルズ コーポレイションＴｅｋｍｉｒａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐｏｒａｔｉｏｎ Lipid composition
MX2012001339A (en) 2009-07-30 2012-03-07 Salvat Lab Sa Apaf-1 inhibitor compounds.
EP2609135A4 (en) 2010-08-26 2015-05-20 Massachusetts Inst Technology Poly(beta-amino alcohols), their preparation, and uses thereof
PL2691443T3 (en) * 2011-03-28 2021-08-30 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
AU2012328570B2 (en) * 2011-10-27 2017-08-31 Massachusetts Institute Of Technology Amino acid derivatives functionalized on the n-terminus capable of forming drug encapsulating microspheres and uses thereof
WO2014028487A1 (en) * 2012-08-13 2014-02-20 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4762915A (en) * 1985-01-18 1988-08-09 Liposome Technology, Inc. Protein-liposome conjugates

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1912679A4 *

Also Published As

Publication number Publication date
US20110009641A1 (en) 2011-01-13
US9006487B2 (en) 2015-04-14
JP2016027057A (en) 2016-02-18
JP2014169288A (en) 2014-09-18
EP1912679A2 (en) 2008-04-23
CN101346468A (en) 2009-01-14
EP2476756A1 (en) 2012-07-18
CA2611944A1 (en) 2006-12-28
CN101346468B (en) 2016-03-30
WO2006138380A2 (en) 2006-12-28
AU2006259415A1 (en) 2006-12-28
JP5777846B2 (en) 2015-09-09
JP2009501699A (en) 2009-01-22
JP2009143960A (en) 2009-07-02
US20160009657A1 (en) 2016-01-14
EP1912679A4 (en) 2009-07-29
AU2006259415B2 (en) 2012-08-30

Similar Documents

Publication Publication Date Title
WO2006138380A3 (en) Amine-containing lipids and uses thereof
WO2002031025A3 (en) Biodegradable poly(beta-amino esters) and uses thereof
WO2004106411A3 (en) Biodegradable poly(beta-amino esters) and uses thereof
MX2021001144A (en) Aminoalcohol lipidoids and uses thereof.
WO2013090861A8 (en) Alpha-aminoamidine polymers and uses thereof
EP2106787A3 (en) Biodegradable block copolymeric compositions for drug delivery
CA2535364A1 (en) Hyaluronic acid nanoparticles
WO2005023176A3 (en) Delivery of physiologixal agents with in-situ gels comprising anionic polysaccharides
WO2004093795A3 (en) Compositions for delivery of drug combinations
WO2011079279A3 (en) Nanoconjugates and nanoconjugate formulations
WO2006009987A3 (en) Dissolvable film composition
EP1881020A4 (en) Polymeric derivative of cytidine metabolic antagonist
WO2009102467A3 (en) Devices, formulations, and methods for delivery of multiple beneficial agents
BRPI0414017B8 (en) multi-arm polymeric prodrug, pharmaceutical composition and method for preparing a multi-arm polymeric prodrug.
WO2007008752A3 (en) Sustained release pharmaceutical compositions for highly water soluble drugs
EP2489372A3 (en) Binding ligand linked drug delivery conjugates of tubulysins
EP2626368A3 (en) Insulin-oligomer conjugates, formulations and uses thereof
EP2266590A3 (en) Active agent delivery sytems and methods for protecting and administering active agents
TW200518775A (en) Pharmaceutical formulations for the prolonged release of active principle(s) and their applications, especially therapeutic applications
EP2374480A3 (en) Mutli-drug ligand conjugates
WO2005067898A3 (en) Improved sustained release compositions for pulmonary administration of insulin
EP1201230A3 (en) Solution-based transdermal drug delivery system comprising a vasodilator
EA200801729A1 (en) Solubilization and targeted delivery of drugs with self-absorbing amphiphilic polymers
WO2007041584A3 (en) Implantable sensors, implantable pumps, and anti-scarring drug combinations
WO2007056205A3 (en) Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680029788.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2611944

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2008517070

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2006259415

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006784878

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006259415

Country of ref document: AU

Date of ref document: 20060614

Kind code of ref document: A